Patent: 8,748,626
✉ Email this page to a colleague
Summary for Patent: 8,748,626
Title: | Oxazole and thiazole compounds as KSP inhibitors |
Abstract: | Disclosed are new substituted oxazole and thiazole compounds of Formula (I) and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses thereof: ##STR00001## |
Inventor(s): | Barsanti; Paul A. (Pleasant Hill, CA), Ding; Yu (Union City, CA), Han; Wooseok (San Ramon, CA) |
Assignee: | Novartis AG (Basel, CH) |
Application Number: | 13/640,561 |
Patent Claims: | see list of patent claims |
Details for Patent 8,748,626
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | See Plans and Pricing | 2039-02-26 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | See Plans and Pricing | 2039-02-26 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | See Plans and Pricing | 2039-02-26 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | See Plans and Pricing | 2039-02-26 |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | See Plans and Pricing | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |